Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...
Abstract: The generation of electrical energy from renewable energy sources (RESs) has increased over the past few decades as part of efforts to reduce humanity's environmental impact. However, their ...
RXRX has upcoming data in H2'25 from the TUPELO trial of REC-4881 in familial adenomatous polyposis. The company will also report data from the ELUCIDATE trial of REC-617 in H2'25. A previous update ...
Hi, I have been using lsp-ai so far successfully with Ollama, but now wanted to try Gemini - since the free tier is quite generous. I am having a weird problem though, where the \n characters are ...
Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...
Abstract: Memoization is a computational technique for speeding up the complexity of computer algorithms. It stores the previously calculated results and invokes them later in the body of the ...
On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...
Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results